This article first appeared on GuruFocus .
Release Date: February 05, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Jubilant Ingrevia Ltd ( BOM:543271 ) reported stable revenues and margins despite challenging market conditions, driven by incremental sales volumes across all segments.
-
The company achieved its second highest volumes in the last 12 quarters, with a 9% volume growth during the quarter.
-
The specialty chemical segment demonstrated resilience with margins above 25%, supported by a favorable product mix and ongoing cost optimization initiatives.
-
The nutrition and health solutions business delivered volume growth both quarter on quarter and year on year, with the vitamin B3 portfolio reaching its highest volumes in the past 7 quarters.
-
Jubilant Ingrevia Ltd ( BOM:543271 ) is making significant progress in its CDMO segment, with increased customer traction and a new multi-purpose plant under construction to enhance capacity.
Negative Points
-
The company is facing sustained pricing pressure across most segments, impacting overall financial performance.
-
Elevated energy costs and weaker demand have contributed to deteriorating financial conditions.
-
The chemical intermediate segment recorded lower realization across key products, leading to a decline in revenue.
-
Despite volume growth, the nutrition segment experienced a 10% year-on-year decline in EBITDA due to price declines in the vitamin B3 portfolio and choline.
-
The European market continues to face headwinds with weak demand and plant closures affecting performance.
Q & A Highlights
-
Warning! GuruFocus has detected 2 Warning Sign with BOM:543271.
-
Is BOM:543271 fairly valued? Test your thesis with our free DCF calculator.
Q: Can you provide insights into the pricing pressures across your segments, specifically Pyridine, B3, and the Acetyl business? A: The pricing pressure in our specialty business, particularly Pyridine and its derivatives, has been evident in the last two quarters. However, we are seeing some uptick in pricing and expect this trend to continue. In the nutrition segment, particularly vitamin B3, we've observed a recent 7-8% price increase. The Acetyl segment, being a commodity, has its own cycles, but we have seen an uptick in acetic acid prices recently, which should positively impact our other products. Overall, we believe the pricing has bottomed out, and we anticipate improvements going forward. (Respondent: Unidentified_2)
Q: Regarding the 100+ product opportunities with a peak potential of 3,500 crores, can you elaborate on the application areas and timeline for realizing these benefits? A: The peak potential of these opportunities typically takes 3-4 years to realize, as it depends on the growth pace of the innovators. We have confirmed 16 molecules with a peak potential of 1,400 crores, and we expect to see revenue from these in the current fiscal year, with significant growth by 2027. The opportunities span across various segments, including CDMO and fine chemicals, with exclusive or semi-exclusive arrangements with customers. (Respondent: Unidentified_2)
Q: Can you provide an update on the agrochemical intermediate project and its expected contribution to this fiscal year? A: The agrochemical intermediate project is on track, with the plant ready and the first batch already charged. We expect the first output within this quarter and have confirmation from the customer to start dispatching. The project is expected to reach full potential by 2027, contributing significantly to our growth. (Respondent: Unidentified_2)
Q: How has the pricing decline impacted your specialty chemical business, and what are your expectations for future growth? A: The pricing decline has offset some of the volume growth in our specialty chemical business. However, we have maintained margins at 25-26% due to cost-saving initiatives and an improved product mix. We expect pricing to recover, leading to a meaningful increase in absolute margins while maintaining percentage margins. (Respondent: Unidentified_2)
Q: When do you expect to see improved margins in the nutrition and health business with a shift towards cosmetics and food segments? A: The shift towards cosmetics and food segments is already underway, but the impact has been offset by price declines in the feed segment. We expect the positive impact to become more prominent as volumes in cosmetics and food increase. Recent price upticks in the feed segment should also help improve margins in the coming quarters. (Respondent: Unidentified_2)
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
